FGFR Inhibitor Tested in Hard-to-Treat GI Cancer

Ariela Katz
Published: Friday, Jan 12, 2018
Milind Javle, MD
Milind Javle, MD
Given that few options are available for intrahepatic cholangiocarcinoma (ICC), investigators are excited about a phase III trial of the multikinase inhibitor derazantinib (ARQ 087) as a second-line treatment for patients with inoperable or advanced disease. Current options are particularly limited for patients who experience disease progression after standard-of-care first-line chemotherapy. In the single-arm trial (NCT03230318), derazantinib is being tested in patients who have a genetic aberration in the fibroblast growth factor receptor 2 (FGFR2) gene.

 

Figure. Derazantinib in FGFR2 Gene Fusion-Positive ICC

Eligible patients will have histologically or cytologically confirmed locally advanced, inoperable, or metastatic ICC with FGFR2 gene fusion status confirmed by next-generation sequencing or fluorescence in situ hybridization testing. Participants must have received at least 1 regimen of prior systemic therapy, with evidence of radiographic progression. Patients who were not able to tolerate prior systemic therapy may also be enrolled.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x